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Prognostic impact of admission 
blood glucose for all-cause mortality 
in patients with acute coronary 
syndromes: added value on top of 
GRACE risk score
Ana T Timóteo1, Ana L Papoila2,3, Pedro Rio1, Fernando 
Miranda4, Maria L Ferreira1 and Rui C Ferreira1
Abstract
Background: Abnormal glucose metabolism is a predictor of worse outcome after acute coronary syndrome (ACS). 
However, this parameter is not included in risk prediction scores, including GRACE risk score. We sought to evaluate 
whether the inclusion of blood glucose at admission in a model with GRACE risk score improves risk stratification.
Methods: Study of consecutive patients included in a single centre registry of ACS. Our primary endpoint was the 
occurrence of all-cause mortality at one-year follow-up. The ability of the two logistic regression models (GRACE risk 
score alone and in combination with blood glucose) to predict death was analysed. Continuous net reclassification 
improvement (NRI) and integrated discrimination improvement (IDI), with corresponding 95% confidence intervals 
(CIs), were also calculated.
Results: We included 2099 patients, with a mean age of 64 (SD=13) years, 69% males. In our sample, 55.1% presented 
with ST-segment elevation ACS and 13.1% in Killip class ≥ 2. Only 25% were known diabetic at admission. In-hospital 
mortality was 5.8% and 9.7% at one-year follow-up. The best cut-point for blood glucose was 160 mg/dl (sensitivity 62% 
and specificity 68%), and 35.2% of the patients had increased levels. This group was elderly, had more prevalence of 
cardiovascular risk factors, worse renal function and GRACE score as well as more frequently Killip class ≥2. Treatment 
was similar in both groups besides less frequent use of clopidogrel in high glycaemic patients. The hyperglycaemia group 
had higher one-year mortality (17.2% vs. 5.6%, p<0.001). Moreover, binary blood glucose remained a predictor of death 
independently of the GRACE risk score and the presence of diabetes (odds ratio (OR) 1.99, 95% CI 1.40–2.84, p<0.001). 
The inclusion of blood glucose, as a continuous variable, in a logistic regression model with GRACE score, increased 
the area under the ROC curve from 0.80 to 0.82 (p=0.018) as well as the goodness-of-fit and was associated with an 
improvement in both the NRI (37%) and the IDI (0.021), suggesting effective reclassification.
Conclusions: A blood glucose level on admission ≥ 160 mg/dl is an independent predictor of mortality in medium-
term follow-up. It offers an incremental predictive value when added to the GRACE risk score, although with a modest 
magnitude of improvement, probably due to the high predictive performance of the GRACE risk score alone.
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Introduction
Elevated admission blood glucose is an important marker 
of worse outcome in patients with myocardial infarction.1 It 
is useful in patients both with and without diabetes.2–9 It is 
usually caused by stress hyperglycaemia induced by cat-
echolamines, which, in turn, are correlated with myocardial 
lesion extension.1 However, risk scores applied in clinical 
practice do not include this variable.
The Global Registry of Acute Coronary Events (GRACE) 
risk score is a validated and established score for risk strati-
fication of patients with acute coronary syndromes, obtained 
from a multicentre registry.10 It is used worldwide with very 
good predictive value for short- and medium-term all-cause 
mortality. It incorporates several clinical and laboratorial 
variables to which a score is given to obtain the final score. 
Although better than previous risk scores, some patients are 
still incorrectly classified and some improvement in predic-
tive accuracy would be important, particularly with the use 
of an easily obtainable variable.
Few studies are found in the literature that assessed the 
incremental prognostic value of admission blood glucose in 
combination with the GRACE risk score. However, these 
studies are somewhat small and showed no significant ben-
efit.11,12 We sought to investigate the incremental value of 
admission blood glucose when considered with the GRACE 
risk score for the prediction of all-cause mortality at one-
year, in a large sample of patients with the whole spectrum 
of acute coronary syndromes.
Methods
This is an observational study of all consecutive patients 
admitted to our intensive care unit (ICU) with ACS (with 
and without ST-segment elevation) during the years 2008 to 
2010. Data were collected prospectively and recorded on a 
computer database of ACS patients admitted to our institu-
tion’s ICU (single-centre registry of ACS). Inclusion crite-
ria were a history of chest pain at rest or other symptoms 
suggestive of an ACS, with the most recent episode occur-
ring within 24 hours of admission. This could be associated 
with new or presumed new significant ST-segment–T wave 
changes/new left bundle branch block or elevated levels of 
biomarkers of myocardial damage (cardiac troponin I and 
creatine kinase). Myocardial infarction was defined by a 
rise and/or fall of cardiac troponin I with at least one value 
above 0.06 ng/ml. We evaluated demographic characteris-
tics of the patients, risk factors for coronary artery disease, 
previous cardiac history, laboratorial data and vital signs on 
admission as well as in-hospital treatment. Automated lab-
oratory equipment (Beckman Coulter LXiTM analyser) was 
used for glucose determination by the glucose-oxidase 
method (coefficient of variation: 2.0%).
We enrolled all consecutive patients if they had a record of 
admission blood glucose. There were no exclusion criteria.
Patients with increased blood glucose on admission 
were defined by a cut-off obtained with the statistical anal-
ysis described below.
Hypertension, diabetes and hyperlipidaemia were 
defined as either previously known or on specific therapy. 
Patients that had smoked during the previous six months 
were classified as smokers and were self-reported. 
Estimated glomerular filtration rate (eGFR) was calculated 
according to the Cockcroft–Gault formula.13 For each 
patient, a numerical scoring according to the previously 
described GRACE risk score was calculated from the initial 
clinical history, electrocardiogram and laboratory values 
collected on admission.10
Follow-up was obtained for every patient that survived to 
discharge by reviewing the medical records and/or by tele-
phone interview with the patient or family members at 30 
days and one year after admission. Follow-up information 
was obtained in 99.8% of the patients. The study primary 
endpoint was all-cause mortality at one-year follow-up.
The study complies with the Declaration of Helsinki and 
informed consent was obtained from all the subjects.
Statistical analysis
Continuous variables are expressed as mean (SD) and 
groups were compared with Student’s t-test. Categorical 
variables are expressed as percentage and Pearson’s chi-
squared test or Fisher’s exact test were used, whenever 
appropriate.
Two logistic regression models were fitted to the data, 
one with the GRACE risk score alone and the other with the 
inclusion of blood glucose as a continuous variable. 
Predictive and discriminative abilities of these models were 
assessed by the Hosmer–Lemeshow goodness of fit test and 
by the area under the receiver operating characteristic 
(ROC) curve (AUC), respectively. The former compares 
the observed frequencies of patients with the event of inter-
est with the expected frequencies based on the values of the 
estimated probabilities obtained by the logistic regression 
models. In this test, a high p-value (non-significant) indi-
cates that the model is performing well and has a good fit. 
The AUC ranges from 0 to 1 and provides a measure of the 
model’s ability to discriminate between those subjects who 
experience the outcome of interest and those who do not. 
An AUC equal to 0.5 means no classification accuracy. To 
compare the AUCs from each of these models, the method 
described by DeLong et al. was used.14
Continuous net reclassification improvement (NRI) and 
integrated discrimination improvement (IDI) were also cal-
culated. The net proportion of patients who died (with 
events) with higher probabilities of death (NRIevents) and of 
patients who did not die (without events) with lower prob-
abilities of death (NRInon-events), were calculated considering 
both models. The NRI is the sum of NRIevents and 
NRInon-events and quantifies the correctness of upward and 
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downward reclassification or movement of predicted prob-
abilities as a result of adding a new marker.15 The IDI is a 
measure of the improvement in prediction and may be 
viewed as the difference between improvement in average 
sensitivity and average 1-specificity.16
Regarding the categorization of blood glucose, mini-
mum p-value approach was used. This method obtains the 
best cut-point from a grid of marker values that is associ-
ated with the minimum chi-squared p-value.17 A new logis-
tic regression model was fitted considering the GRACE 
risk score and the categorized blood glucose, as independ-
ent variables.
For all comparisons, a p-value ≤ 0.05 was considered 
statistically significant. Whenever appropriate, 95% confi-
dence intervals (CIs) were calculated.
Statistical analysis was carried out using IBM SPSS 
Statistics, Version 19.0 (IBM Corp., North Castle, NY, 
USA) and R software.18
Results
From a total of 2216 consecutive patients included in our 
registry, 2099 had information about admission blood glu-
cose and were included in the study, with a mean age of 64 
(SD=13) years, 69% males. The population baseline char-
acteristics are described in Table 1. The in-hospital, 30-day 
and one-year mortality rates were 5.1%, 5.8% and 7.8% 
respectively.
By ROC curve analysis, the AUC of blood glucose for 
the prediction of one-year mortality was 0.68 (95% CI 
0.64–0.72). Univariable analysis showed that blood glu-
cose at admission, as a continuous variable, is a predictor of 
outcome (OR 1.07, 95% CI 1.05–1.08, p < 0.001, per 10 
mg/dl increase) and it remained an independent predictor of 
mortality after adjustment for the GRACE risk score and 
for the presence of diabetes (OR 1.04, 95% CI 1.02–1.06, p 
< 0.001).
Models with GRACE risk score alone and after inclu-
sion of blood glucose were then fitted to the data. The AUC 
increased significantly after the inclusion of blood glucose 
in the model (AUC=0.80 vs. AUC=0.82; p=0.018) (Figure 
1) as did the goodness of fit (Table 2). Overall, the inclu-
sion of blood glucose in a model with GRACE risk score 
was associated with a NRI of 37%, suggesting effective 
reclassification. Significant reclassification occurred 
mainly in the non-events group. In fact, for NRI non-
events, a net 48% of patients who did not die had a sub-
stantial and significant reduction of the calculated risk. 
The IDI again showed that the model performance was 
improved by adding blood glucose to the GRACE risk 
score (IDI = 0.021) and, although modest, it was statisti-
cally significant.
Aware of the importance of biomarker cut-points in 
daily clinical practice, minimum p-value approach was 
used in order to find the blood glucose level that best 
discriminates the occurrence of all-cause mortality at 
one-year follow-up. A value of 160 mg/dl was obtained 
(Figure 2), with a sensitivity of 62% and a specificity of 
68%. Patients with increased blood glucose were older, 
less often males, and had more risk factors for coronary 
artery disease, as well as previous stroke/transient 
ischemic attack (Table 1). They presented more often as a 
STEMI and with signs of heart failure. Renal insuffi-
ciency was more prevalent. They were more often sub-
mitted to coronary angiography and had more multivessel 
disease. Treatment was similar, except for clopidogrel, 
which was less frequently prescribed in patients with 
increased admission glucose. Mortality was significantly 
higher in this group (p<0.001).
Finally, the results of a new logistic regression model 
showed that blood glucose, as a binary variable, remained a 
predictor of death independently of the GRACE risk score 
and the presence of diabetes (OR 1.99, 95% CI 1.40–2.84, 
p<0.001).
Discussion
Elevated blood glucose level at admission for myocardial 
infarction is associated with worse outcome in both non-
diabetic and diabetic patients.1–9 In fact, in a broad ACS 
population, hyperglycaemia at admission is a short-term 
and long-term prognostic marker.1 A high glucose level at 
admission is often attributed to ‘stress hyperglycaemia’ 
and might reflect an acute response to the hyperadrenergic 
state, with catecholamine release and induction of glycog-
enolysis.1 It is also associated with the increase in free 
fatty acids, insulin resistance, inactivation of nitric oxide 
and the production of oxygen reactive species, generating 
oxidative stress, as well as enhanced thrombin formation, 
platelet activation and fibrin clot resistance to lysis.1,19 
Hyperglycaemia is associated with impaired coronary flow 
before reperfusion therapy in ST-elevation myocardial 
infarction patients.20
A report from the GRACE registry showed that short-
term and six-month mortality was increased significantly 
with higher admission glucose levels in patients across the 
whole spectrum of acute coronary syndromes.1 This asso-
ciation is probably mainly driven by an increased risk of 
early death, consistent with the paradigm that admission 
glucose level is a marker of stress rather than a reflection of 
a general glucometabolic state.21 A U-shaped curve of risk 
associated with admission glucose level is described, con-
sistent with previous reports of adverse outcome associated 
with low levels (< 100 mg/dl) in patients presenting with an 
acute myocardial infarction and in diabetic patients with 
ACS.1,22 It might be related to inadequate stress response. 
This registry also showed the association between fasting 
glucose levels and short-term and six-month mortality, sug-
gesting that this might be a better independent marker than 
admission glucose level.1
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Two previously published papers showed no benefit in 
risk stratification after ACS with the inclusion of admission 
blood glucose in a logistic regression model with GRACE 
risk score. However, the samples were relatively small and 
in one case only hospital mortality was analysed.11,12
Correia et al. studied a small sample (148 patients) with 
only non-ST segment elevation ACS.11 There was no benefit 
in either AUC or NRI. Admission blood glucose was intro-
duced directly inside the GRACE risk score model without 
any type of validation. De Mulder et al. studied a larger sam-
ple (550 patients), but the inclusion period was from 2003 to 
2006, and does not reflect contemporary treatment.12 Both 
AUC and NRI improvement showed a trend, although not of 
statistical significance. The data from our large and unse-
lected population confirmed that admission glucose is an 
independent predictor of all-cause mortality in the whole 
spectrum of acute coronary syndromes, even after adjust-
ment for diabetic status and GRACE risk score. They also 
showed significant benefit in risk stratification after the 
inclusion in a model with the GRACE risk score.
Mere associations with incident all-cause mortality, 
although important, do not automatically mean that adding 
a new marker to traditional risk prediction models will 
improve outcome risk prediction. Therefore, we performed 
Table 1. Clinical characteristics of both groups according to glucose levels.
Total
n=2099
Glucose < 160 mg/dl
n=1361
Glucose ≥ 160 mg/dl
n=738
p-value
Age (years) 64 ± 13 63 ± 13 66 ± 14 <0.001
Male gender (%) 69.1 71.1 65.3 0.007
Risk factors (%)  
 Hypertension 65.7 63.0 70.7 <0.001
 Hyperlipidaemia 49.8 51.5 46.6 0.036
 Diabetes 25.5 10.9 52.4 <0.001
 Smoking 36.4 40.4 29.0 <0.001
Previous history (%)  
 Myocardial infarction 15.7 15.5 16.1 0.756
 PCI 10.5 11.5  8.7 0.055
 CABG  4.2  3.7  5.1 0.159
 Stroke/TIA  6.3  5.1  8.5 0.002
Initial presentation  
 STEMI (%) 55.1 52.5 59.8 0.002
 Killip class >1 (%) 13.1  8.4 21.8 <0.001
 Heart rate (beats/min) 78 ± 19 76 ± 18 81 ± 21 <0.001
 Systolic blood pressure (mmHg) 133 ± 28 134 ± 28 132 ± 29 0.121
Laboratory data  
 eGFR < 60 ml/min per 1.73 m2 (%) 28.1 24.2 35.4 <0.001
 Blood glucose (mg/dl) 163 ± 82 119 ± 21 244 ± 90 <0.001
GRACE risk score 145 ± 36 138 ± 34 158 ± 36 <0.001
LVEF < 35% (%) 7.5 5.2 11.8 <0.001
Coronary angiography (%) 76.9 75.5 79.5 0.032
 Multivessel disease 66.8 63.1 72.7 <0.001
Treatment (%)  
 ASA 97.4 97.7 96.7 0.234
 Clopidogrel 93.3 94.1 91.7 0.046
 ACEI 86.7 86.3 87.3 0.596
 Beta-blocker 81.8 82.4 80.9 0.438
 Statin 92.6 93.3 91.2 0.093
 PCI 74.6 74.2 75.3 0.607
 CABG  1.1  1.0  1.4 0.535
All-cause mortality (%)  
 In-hospital mortality  5.1  2.8 11.2 <0.001
 One-year mortality  7.8  5.6 17.2 <0.001
PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; TIA: transient ischemic attack; STEMI: ST elevation myocardial 
infarction; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; ASA: acetylsalicylic acid; ACEI: angiotensin converting 
enzyme inhibitor
 by guest on April 4, 2014acc.sagepub.comDownloaded from 
Timóteo et al. 5
tests to discriminate and calibrate different prediction 
models. Discriminative analysis of a model with GRACE 
risk score alone and after admission glucose inclusion 
showed that the AUC increased significantly. The predic-
tive performance also improved. Considering the other 
new statistical metrics, recently proposed, to quantify the 
degree of correct reclassification, the inclusion of glucose 
in a model with GRACE risk score was associated with a 
NRI of 37%, suggesting effective reclassification. The 
new model better identifies the group without events. The 
IDI again showed that the model performance was signifi-
cantly, although slightly, improved by adding glycaemia to 
the GRACE risk score.
The magnitude of improvement was small. However, in 
the presence of a fairly robust risk score, such as in the case 
of the GRACE risk score, the quantitative improvement in 
model performance introduced by adding new variables to 
the existing model is expected to be small. Also the new 
model better identifies those who do not have events than 
those who do. The new model significantly reduced the cal-
culated risk in 48% of those without events. Thus the new 
model (with the addition of admission blood glucose to 
GRACE score) is better at identifying ‘truly low-risk’ 
patients and is as good as in identifying patients who develop 
events. This might not be ideal when we are evaluating a risk 
score to identify high-risk patients. However, recent cardio-
vascular disease guidelines are encouraging a practice shift 
toward greater focus on identification of ‘truly low-risk’ 
patients instead of focusing on identification of high-risk 
patients. This allows a better selection of patients avoiding 
unnecessary interventions that might increase costs as well 
as the risk of procedure-related adverse events.
Limitations
This is a single-centre study, which might limit its conclu-
sions. It is also a retrospective study. It might not be 
applicable to other populations with different baseline char-
acteristics. In particular, our population has a predominance 
of ST elevation myocardial infarction patients, explained 
by the fact that we are a tertiary centre which receives many 
patients from other hospitals for primary percutaneous 
coronary intervention. However, this does not reflect the 
Figure 1. ROC curve analysis comparing the GRACE risk 
score and the new model with the inclusion of blood glucose 
(p-value = 0.018).
Table 2. Statistics for model improvement with the addition of 
blood glucose.
Events (n)  203
Non-events (n) 1896
Continuous NRI (%)  
 cNRIevents –10 (–24 to 3)
 cNRInon-events 48 (44 to 52)
 cNRI 37 (23 to 52)
IDI statistics  
 IDIevents 0.019
 IDInon-events 0.002
 IDI 0.021 (0.008 to 0.033)
AUC  
 GRACE risk score 0.80 (0.77–0.84)
 Combination model 0.82 (0.79–0.85)
 Difference (p-value) 0.018
Goodness of fit (GRACE risk score)a 0.732
Goodness of fit (combination model)a 0.946
The 95% confidence intervals are shown in parenthesis.
aHosmer–Lemeshow goodness of fit test (p-value).
NRI: net reclassification improvement; IDI: integrated discrimination im-
provement; AUC: area under the receiver operator characteristic curve
Figure 2. Resulting plot of minimum p-value approach. Chi-
squared values measuring the association between death at 
one-year follow-up and dichotomized blood glucose are plotted 
as a function of different blood glucose cut-points. The shape of 
the plot suggests the existence of a cut-point at 160 mg/dl.
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distribution in other cohort studies of ACS and some cau-
tion should be used when translating our results for other 
cohorts.
The cut-off proposed by the present work was not exter-
nally validated. However, other authors from Spain and Italy 
(Mediterranean countries) proposed similar cut-offs (140 mg/
dl and 170 mg/dl, respectively).23–25 Other, Eastern European, 
countries suggest higher cut-points (≥ 200 mg/dl).26,27 
Probably there is some genetic/environmental explanation for 
these results and local studies seem to be important.
Conclusions
In a population of patients with the whole spectrum of acute 
coronary syndromes, blood glucose adds prognostic infor-
mation to established risk factors, even in combination with 
the GRACE risk score. A level at admission ≥ 160 mg/dl is 
an independent predictor of mortality in medium-term fol-
low-up. We encourage its wider use.
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